Soligenix, Inc. (SNGX) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(Qt=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Ft)),notifLabel:document.querySelector(".".concat(Gt))};no(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

0.3100 -0.0001 (-0.03%)

At close: June 5 at 4:00 PM EDT

0.3179 +0.01 (+2.55%)

After hours: June 5 at 7:49 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for SNGX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 0.3101
• Open 0.3110
• Bid 0.3004 x 500
• Ask 0.3112 x 100
• Day's Range 0.3003 - 0.3418
• 52 Week Range 0.3000 - 2.0000
• Volume 985,837
• Avg. Volume 2,731,739
• Market Cap (intraday) 306,121
• Beta (5Y Monthly) 1.93
• PE Ratio (TTM) --
• EPS (TTM) -9.7600
• Earnings Date Aug 19, 2024 - Aug 23, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 2.50

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

www.soligenix.com

13

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Soligenix, Inc.

Recent News: SNGX

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

Soligenix, Inc. (SNGX) Latest Stock News & Headlines - Yahoo FinanceSoligenix, Inc. Common Stock (SNGX) Stock Price & News - Google FinanceSoligenix Inc Stock Price and Quote

View More

Performance Overview: SNGX

Trailing total returns as of 6/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SNGX

59.21%

S&P 500

12.25%

1-Year Return

SNGX

56.94%

S&P 500

25.02%

3-Year Return

SNGX

98.09%

S&P 500

26.58%

5-Year Return

SNGX

97.05%

S&P 500

90.99%

Compare To: SNGX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

SNGXSoligenix, Inc.

0.3100

-0.03%

Mkt Cap 306,121

Industry Biotechnology

CNSPCNS Pharmaceuticals, Inc.

5.39

-16.37%

Mkt Cap 1.278M

Industry Biotechnology

THARTharimmune, Inc.

5.17

+1.37%

Mkt Cap 4.064M

Industry Biotechnology

ADTXAditxt, Inc.

2.0100

+4.69%

Mkt Cap 3.347M

Industry Biotechnology

AZTRAzitra, Inc.

0.1684

-1.52%

Mkt Cap 4.851M

Industry Biotechnology

TVGNTevogen Bio Holdings Inc.

0.7768

-1.53%

Mkt Cap 129.037M

Industry Biotechnology

ABVCABVC BioPharma, Inc.

0.7762

-2.30%

Mkt Cap 8.423M

Industry Biotechnology

DRMADermata Therapeutics, Inc.

3.7187

+3.01%

Mkt Cap 1.651M

Industry Biotechnology

LIXTLixte Biotechnology Holdings, Inc.

2.5250

+2.23%

Mkt Cap 5.679M

Industry Biotechnology

PBMPsyence Biomedical Ltd.

0.7538

+2.96%

Mkt Cap 10.094M

Industry Biotechnology

DBVTDBV Technologies S.A.

0.5799

+1.38%

Mkt Cap 124.592M

Industry Biotechnology

Statistics: SNGX

View More

Valuation Measures

Annual

As of 6/5/2024

• Market Cap

  4.90M

• Enterprise Value

  1.01M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  --

• Price/Book (mrq)

  6.37

• Enterprise Value/Revenue

  1.87

• Enterprise Value/EBITDA

  --

Financial Highlights

Profitability and Income Statement

• Profit Margin

  0.00%

• Return on Assets (ttm)

  -50.00%

• Return on Equity (ttm)

  --

• Revenue (ttm)

  699.21k

• Net Income Avi to Common (ttm)

  -7.01M

• Diluted EPS (ttm)

  -9.7600

Balance Sheet and Cash Flow

• Total Cash (mrq)

  7.09M

• Total Debt/Equity (mrq)

  416.52%

• Levered Free Cash Flow (ttm)

  -5.64M

View More

Research Analysis: SNGX

View More

View More

Company Insights: SNGX

Research Reports: SNGX

View More

View More

People Also Watch

TENX Tenax Therapeutics, Inc.

3.5800

+1.99%

MBRX Moleculin Biotech, Inc.

4.8900

+7.71%

OPGN OpGen, Inc.

2.7100

-5.90%

PHIO Phio Pharmaceuticals Corp.

0.7200

-1.32%

HOTH Hoth Therapeutics, Inc.

1.1510

-1.62%

VTVT vTv Therapeutics Inc.

19.00

-9.95%

PULM Pulmatrix, Inc.

1.9700

+2.07%

SNOA Sonoma Pharmaceuticals, Inc.

0.1900

-2.06%

CAPR Capricor Therapeutics, Inc.

5.62

-3.10%

VTGN Vistagen Therapeutics, Inc.

3.9000

-1.02%

CLRB Cellectar Biosciences, Inc.

3.1100

+6.87%

DARE Daré Bioscience, Inc.

0.4288

+0.82%

XBIO Xenetic Biosciences, Inc.

4.0236

+0.34%

CYCC Cyclacel Pharmaceuticals, Inc.

2.1200

-2.30%

CTXR Citius Pharmaceuticals, Inc.

0.6402

+0.34%

TCON TRACON Pharmaceuticals, Inc.

1.2200

-2.40%